Inbiomotion — No stage disclosed

Inbiomotion, an IRB Barcelona spin-off behind the MAF biomarker test for early breast cancer, closed an oversubscribed round of undisclosed size led by Alta Life Sciences, with existing investor ICF.

LeadAlta Life Sciences RoundNo stage disclosed Announced21 Jan 2021 CityBarcelona SectorHealthtech & Bio · Diagnostics / Oncology Source W

Something wrong? Suggest a correction →